• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Keros Therapeutics, Inc. - common stock (NQ:KROS)

    15.22 +0.19 (+1.26%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Keros Therapeutics, Inc. - common stock

    < Previous 1 2 3 Next >
    Keros Therapeutics Stock Meets 80-Plus RS Rating Benchmark
    Building your watch list, look for stocks with an 80-plus RS Rating. Keros Therapeutics stock just met that criteria with a new score of 86. 
    Via Investor's Business Daily
    Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
     
    Via Benzinga
    Vaxcyte, Shoals Technologies, Polestar Automotive, Applied Optoelectronics And Other Big Stocks Moving Higher On Tuesday
     
    Via Benzinga
    Keros Therapeutics Inc. (NASDAQ: KROS) Near the Top of Equities by Percentage Gain on 1/4
    Via Investor Brand Network
    Where Keros Therapeutics Stands With Analysts
     
    Via Benzinga
    KROS Stock Earnings: Keros Therapeutics Misses EPS for Q2 2024
    KROS stock results show that Keros Therapeutics missed analyst estimates for earnings per share the second quarter of 2024. 
    Via InvestorPlace
    Analyst Sees Keros Therapeutics As Next Acceleron, Set For Major Biotech Growth
    Keros Therapeutics is advancing novel therapies for hematological and cardiopulmonary disorders via TGF-β signaling regulation. Oppenheimer rates KROS Outperform with a $102 price target. 
    Via Benzinga
    KROS Stock Earnings: Keros Therapeutics Beats EPS for Q1 2024
    KROS stock results show that Keros Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
    Via InvestorPlace
    Why Mobileye Global Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Shares of Mobileye Global Inc. (NASDAQ: MBLY) fell sharply during Thursday’s session after the company issued preliminary FY23 financial results and initial 2024 guidance.< 
    Via Benzinga
    Recap: Keros Therapeutics Q1 Earnings
     
    Via Benzinga
    Recap: Keros Therapeutics Q3 Earnings
    Keros Therapeutics (NASDAQ:KROS) reported its Q3 earnings results on Thursday, November 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
    Via Benzinga
    Keros Therapeutics Posts Preliminary Data Early-Stage KER-012 Trial
     
    Via Benzinga
    Lamb Weston Posts Upbeat Results, Joins Omega Therapeutics, Allstate And Other Big Stocks Moving Higher On Thursday
    U.S. stocks traded mostly higher, with the Dow Jones index gaining around 150 points on Thursday. Shares of Lamb Weston Holdings, Inc. (NYSE: LW) rose during Thursday’s session following... 
    Via Benzinga
    Topics Stocks
    Why bluebird bio Shares Are Trading Higher? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Shares of bluebird bio, Inc. (NASDAQ: BLUE) rose sharply during Monday’s session after the company presented updated data from its gene therapy program in transfusion-dependent beta-thalassemia at the... 
    Via Benzinga
    Keros Therapeutics Posts Encouraging Preclinical Data Of RKER-012 In Type Of High Blood Pressure
     
    Via Benzinga
    Coinbase, Riot Platforms, Marathon Digital And Other Big Stocks Moving Lower On Monday
    U.S. stocks traded mostly mixed, with the Dow Jones index gaining more than 100 points on Monday. Here are some other big stocks recording losses in today’s session. 
    Via Benzinga
    Topics Stocks
    Benzinga's Top Ratings Upgrades, Downgrades For July 31, 2023
     
    Via Benzinga
    Benzinga's Top Ratings Upgrades, Downgrades For July 26, 2023
     
    Via Benzinga
    Why American Software Shares Are Trading Lower By Over 20%? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Gainers Advanced Health Intelligence Ltd. (NASDAQ: AHI) shares jumped 144.5% to $0.7827. 
    Via Benzinga
    Why Shares of Keros Therapeutics Jumped This Week
    The company appointed a new director and an analyst reiterated his position on the stock. 
    Via The Motley Fool
    Benzinga's Top Ratings Upgrades, Downgrades For February 14, 2023
     
    Via Benzinga
    BioMedNewsBreaks – Keros Therapeutics Inc. (NASDAQ: KROS) Presents Clinical and Preclinical Data from Its Lead Hematological Programs at 64th ASH Event
    Via Investor Brand Network
    Benzinga's Top Ratings Upgrades, Downgrades For October 18, 2022
    Upgrades 
    Via Benzinga
    Why Shares of Keros Therapeutics Rose 10.2% This Week
    A sympathetic reaction to a competitor's drug helped push the clinical-stage pharmaceutical company's shares higher. 
    Via The Motley Fool
    Alphatec Holdings, Immatics And Some Other Big Stocks Moving Higher On Monday
    U.S. stocks traded lower, with the Dow Jones dropping more than 100 points on Monday. Here are some big stocks recording gained in today’s session. 
    Via Benzinga
    Benzinga's Top Ratings Upgrades, Downgrades For July 26, 2022
    Upgrades 
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's Intraday Session
     
    Via Benzinga
    Stocks That Hit 52-Week Lows On Thursday
    On Thursday, 216 stocks hit new 52-week lows. 
    Via Benzinga
    76 Biggest Movers From Yesterday
    Gainers Bright Green Corp. (NASDAQ: BGXX) jumped 90.5% to close at $48.08 on Wednesday. Bright Green Corporation, went public on the NASDAQ Tuesday, becoming the first U.S. plant-touching company to... 
    Via Benzinga
    The Daily Biotech Pulse: Pfizer/BioNTech's COVID-19 Booster For Kids, Moderna Starts First African Trial Of mRNA HIV Vaccine, Tonix Extends COVID-19 Antiviral Research Pact
    Here's a roundup of top developments in the biotech space over the last 24 hours. 
    Via Benzinga
    < Previous 1 2 3 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.